Open Access
Med Sci (Paris)
Volume 36, Number 2, Février 2020
Page(s) 112 - 115
Section Le Magazine
Published online 04 March 2020
  1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [Google Scholar]
  2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 ; 366 : 2443–2454. [Google Scholar]
  3. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 ; 366 : 2455–2465. [Google Scholar]
  4. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 2018 ; 118 : 9–16. [CrossRef] [PubMed] [Google Scholar]
  5. Perrot I, Michaud HA, Giraudon-Paoli M, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 2019 ; 27 : 2411–25 e9. [Google Scholar]
  6. de Andrade Mello P, Coutinho-Silva R, Savio LEB. Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol 2017; 8 : 1526. [CrossRef] [PubMed] [Google Scholar]
  7. Silva-Vilches C, Ring S, Mahnke K. ATP and its metabolite adenosine as regulators of dendritic cell activity. Front Immunol 2018 ; 9 : 2581. [CrossRef] [PubMed] [Google Scholar]
  8. Bastid J, Regairaz A, Bonnefoy N, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2015 ; 3 : 254–265. [CrossRef] [PubMed] [Google Scholar]
  9. Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4+ Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterol 2010 ; 139 : 1030–1040. [CrossRef] [Google Scholar]
  10. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011 ; 71 : 2892–2900. [Google Scholar]
  11. Stagg J, Beavis PA, Divisekera U, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012 ; 72 : 2190–2196. [Google Scholar]
  12. Antonioli L, Yegutkin GG, Pacher P, et al. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer 2016 ; 2 : 95–109. [CrossRef] [PubMed] [Google Scholar]
  13. Antonioli L, Novitskiy SV, Sachsenmeier KF, et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov Today 2017 ; 22 : 1686–1696. [CrossRef] [PubMed] [Google Scholar]
  14. Nikolova M, Carriere M, Jenabian MA, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011 ; 7 : e1002110. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.